Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label Study of the Effect of First-line Herceptin in Combination With a Fluoropyrimidine and Cisplatin Versus Chemotherapy Alone on Overall Survival in Patients With HER2-positive Advanced Gastric Cancer
Brief Summary: This parallel, randomized, open-label, multi-centre study will evaluate the effect on overall survival of trastuzumab (Herceptin) in combination with a chemotherapy compared to the chemotherapy alone in patients with HER2-positive advanced gastric cancer. Trastuzumab (Herceptin) will be administered as intravenous infusion of 6 mg/kg (loading dose 8 mg/kg) every 3 weeks. The chemotherapy consists of a combination of 6 cycles of fluorouracil (800 mg/m2/day intravenous infusion every 3 weeks) and cisplatin (80 mg/m2 intravenous infusion every 3 weeks), or capecitabine (Xeloda, 1000 mg/m2 po twice daily for 14 days every 3 weeks) and cisplatin (80 mg/m2 intravenous infusion every 3 weeks). Treatment with trastuzumab (Herceptin) will continue until disease progression. The target sample size is 300-600 patients.


Options:
A: Arm Label: 1- Docetaxel plus Oxaliplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Drug: oxaliplatin | Arm Label: 2- Docetaxel plus oxaliplatin plus cetuximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Drug: cetuximab, Drug: oxaliplatin | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): 1- Docetaxel plus Oxaliplatin, 2- Docetaxel plus oxaliplatin plus cetuximab | Intervention Type: DRUG; Name: cetuximab; Assigned to Arm(s): 2- Docetaxel plus oxaliplatin plus cetuximab | Intervention Type: DRUG; Name: oxaliplatin; Assigned to Arm(s): 1- Docetaxel plus Oxaliplatin, 2- Docetaxel plus oxaliplatin plus cetuximab
B: Arm Label: Trastuzumab, Fluoropyrimidine, Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: Trastuzumab, Drug: Fluorouracil, Drug: Cisplatin, Drug: Capecitabine | Arm Label: Fluoropyrimidine, Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluorouracil, Drug: Cisplatin, Drug: Capecitabine | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): Trastuzumab, Fluoropyrimidine, Cisplatin | Intervention Type: DRUG; Name: Fluorouracil; Assigned to Arm(s): Fluoropyrimidine, Cisplatin, Trastuzumab, Fluoropyrimidine, Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Fluoropyrimidine, Cisplatin, Trastuzumab, Fluoropyrimidine, Cisplatin | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Fluoropyrimidine, Cisplatin, Trastuzumab, Fluoropyrimidine, Cisplatin
C: Arm Label: CapeOx plus Lapatinib; Type: EXPERIMENTAL; Interventions: Drug: Lapatinib, Drug: Capecitabine, Drug: Oxaliplatin | Arm Label: CapeOx plus Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Capecitabine, Drug: Oxaliplatin | Intervention Type: DRUG; Name: Lapatinib; Assigned to Arm(s): CapeOx plus Lapatinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CapeOx plus Placebo | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): CapeOx plus Lapatinib, CapeOx plus Placebo | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): CapeOx plus Lapatinib, CapeOx plus Placebo
D: Arm Label: Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel; Type: EXPERIMENTAL; Interventions: Biological: Ramucirumab (IMC-1211B) DP, Drug: Paclitaxel | Arm Label: Placebo and Paclitaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Paclitaxel | Intervention Type: BIOLOGICAL; Name: Ramucirumab (IMC-1211B) DP; Assigned to Arm(s): Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo and Paclitaxel | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo and Paclitaxel, Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel

Answer: B